Recent advances of drug delivery nanocarriers in osteosarcoma treatment

• Published in: Journal of Cancer 2020, Vol.11 (1), p.69-82
• Main Authors: Wang, Shang-Yu, Hu, Hong-Zhi, Qing, Xiang-Cheng, Zhang, Zhi-Cai, Shao, Zeng-Wu
• Format: Article
• Language: English
• Subjects: Acids; Biocompatibility; Bone cancer; Cancer therapies; Chemotherapy; Clinical trials; Drug delivery systems; Drug dosages; FDA approval; Keratin; Lipids; Nanomaterials; Nanoparticles; Polyethylene glycol; Polymers; Review; Tumors
• ISSN: 1837-9664; 1837-9664
• DOI: 10.7150/jca.36588

Osteosarcoma is the most common primary malignant bone tumor mainly occurred in children and adolescence, and chemotherapy is limited for the side effects and development of drug resistance. Advances in nanotechnology and knowledge of cancer biology have led to significant improvements in developing tumor-targeted drug delivery nanocarriers, and some have even entered clinically application. Delivery of chemotherapeutic agents by functionalized smart nanocarriers could protect the drugs from rapid clearance, prolong the circulating time, and increase the drug concentration at tumor sites, thus enhancing the therapeutic efficacy and reducing side effects. Various drug delivery nanocarriers have been designed and tested for osteosarcoma treatment, but most of them are still at experimental stage, and more further studies are needed before clinical application. In this present review, we briefly describe the types of commonly used nanocarriers in osteosarcoma treatment, and discuss the strategies for osteosarcoma-targeted delivery and controlled release of drugs. The application of nanoparticles in the management of metastatic osteosarcoma is also briefly discussed. The purpose of this article is to present an overview of recent progress of nanoscale drug delivery platforms in osteosarcoma, and inspire new ideas to develop more effective therapeutic options.